Pavmed Stock Price, News & Analysis

PAVmed Inc. (PAVM, PAVMZ) announced the appointment of Sunny Webb as Chief Technology Officer for its subsidiary Veris Health. Ms. Webb brings nearly two decades of experience in technology leadership, having worked with major companies like Apple and Facebook. She aims to enhance Veris' capabilities in creating integrated digital healthcare solutions for cancer patients. The company is targeting FDA clearance for its innovative implantable vascular access port by H2-2022, leveraging partnerships with Microsoft and Loka Inc. for advanced software development.

Lucid Diagnostics Inc. (Nasdaq: LUCD) appointed Dr. Suman M. Verma as Chief Scientific Officer, strengthening its leadership in cancer prevention diagnostics. Dr. Verma previously led the transfer of the EsoGuard^® Esophageal DNA Test to commercial settings. Her expertise in molecular diagnostics is expected to enhance the development of Lucid's tests for patients with gastroesophageal disease. The company is focused on advancing the early detection of esophageal cancer through its innovative diagnostic tools, including EsoGuard and EsoCheck.

Lucid Diagnostics Inc. has completed its initial public offering (IPO) on October 18, 2021, selling 5,000,000 shares at $14.00 each, raising $70 million in gross proceeds. The underwriters hold a 30-day option for an additional 750,000 shares. Lucid, a cancer prevention diagnostics company, focuses on gastroesophageal disease (GERD) patients at risk of esophageal cancer. Its EsoGuard® test is the first non-invasive diagnostic tool for early detection of esophageal precancer in at-risk patients. Cantor and Canaccord Genuity are joint book-running managers for the offering.

Lucid Diagnostics Inc. has announced the pricing of its initial public offering (IPO) of 5 million shares at $14.00 per share, aiming to raise $70 million before expenses. The IPO will launch on October 14, 2021, and is expected to close on or around October 18, 2021. The underwriters have a 30-day option to purchase an additional 750,000 shares. Lucid, a subsidiary of PAVmed Inc., focuses on cancer prevention, particularly for patients suffering from gastroesophageal disease at risk of esophageal cancer, using its EsoGuard® diagnostic test.

PAVmed Inc. announced that a wholly owned subsidiary has signed a purchase agreement for CapNostics, LLC, maker of the EsophaCap® device, which is FDA-cleared and CE Mark certified for non-endoscopic esophageal cell collection. This acquisition aims to enhance PAVmed's portfolio in early detection and monitoring of esophageal diseases, particularly esophageal precancer. The deal includes a long-term consulting agreement with Martin Von Dyck, the owner of CapNostics, and a manufacturing agreement with its contract manufacturer. This strategic move is expected to drive shareholder value.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced a virtual investor event on October 26, 2021, from 1 to 3 PM EDT, focused on its digital health subsidiary, Veris Health. The event will showcase Veris’ innovative technology aimed at enhancing cancer care through remote monitoring and data analytics. Panelists include executives from PAVmed and the Stanford Cancer Institute. Veris seeks FDA clearance for its intelligent implantable vascular access port, targeting a launch for H2 2022. The event includes a Q&A session for participant engagement.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) recently announced that its subsidiary, Lucid Diagnostics Inc., has filed a Form S-1 registration with the SEC for a proposed initial public offering of its common stock. The offering details, including the number of shares and price range, are yet to be determined. Lucid intends to list on Nasdaq under the ticker 'LUCD.' Cantor Fitzgerald & Co. and Canaccord Genuity LLC will manage the offering, with BTIG, LLC and Needham & Co., LLC as co-managers. This offering aims to bolster Lucid’s market presence and product development.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced that its subsidiary Veris Health Inc. has joined Microsoft for Startups, gaining access to advanced technology and support to expedite its remote digital healthcare platform focused on cancer care. Veris is collaborating with Loka Inc. for platform development on Microsoft Azure, integrating AI and IoT for better patient monitoring. Veris aims for FDA clearance of its intelligent implantable vascular access port by H2-2022, enhancing data-driven patient care and optimizing treatment outcomes.